CYTEK BIOSCIENCES DL-001
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhan… Read more
CYTEK BIOSCIENCES DL-001 (8EQ) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CYTEK BIOSCIENCES DL-001 (8EQ) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CYTEK BIOSCIENCES DL-001 - Net Assets Trend (None–None)
This chart illustrates how CYTEK BIOSCIENCES DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CYTEK BIOSCIENCES DL-001 (None–None)
The table below shows the annual net assets of CYTEK BIOSCIENCES DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CYTEK BIOSCIENCES DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CYTEK BIOSCIENCES DL-001 Competitors by Market Cap
The table below lists competitors of CYTEK BIOSCIENCES DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
enCore Energy Corp. Common Shares
NYSE MKT:EU
|
$361.80 Million |
|
Guangdong Xinhui Meida Nylon Co Ltd
SHE:000782
|
$361.89 Million |
|
Karooooo Ltd
NASDAQ:KARO
|
$361.96 Million |
|
Zepp Health Corp
NYSE:ZEPP
|
$362.08 Million |
|
Kinepolis Group NV
BR:KIN
|
$361.75 Million |
|
COGECO INC. SUB.VTG
F:76E
|
$361.52 Million |
|
Fujian Yongfu Power Engineering Co Ltd Class A
SHE:300712
|
$361.49 Million |
|
Nantong Haixing Electronics Co Ltd
SHG:603115
|
$361.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CYTEK BIOSCIENCES DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CYTEK BIOSCIENCES DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CYTEK BIOSCIENCES DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CYTEK BIOSCIENCES DL-001's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $253,026,393
- Average return on equity (ROE) among peers: -74.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CYTEK BIOSCIENCES DL-001 (8EQ) | €- | N/A | N/A | $361.80 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |